Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.

Li C, Lee KC, Schneider EB, Zeiger MA.

J Clin Endocrinol Metab. 2012 Dec;97(12):4559-70. doi: 10.1210/jc.2012-2104.

2.

The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera A, Vitti P, Basolo F.

J Clin Endocrinol Metab. 2012 Dec;97(12):4390-8. doi: 10.1210/jc.2012-1775.

PMID:
23066120
3.

Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.

Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.

Endocr Relat Cancer. 2016 Jan;23(1):27-34. doi: 10.1530/ERC-15-0408.

PMID:
26598713
4.

Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.

Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.

Exp Clin Endocrinol Diabetes. 2014 May;122(5):268-72. doi: 10.1055/s-0034-1372624.

PMID:
24839220
5.

Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.

Zhang Q, Liu SZ, Zhang Q, Guan YX, Chen QJ, Zhu QY.

Cell Physiol Biochem. 2016;38(2):763-76. doi: 10.1159/000443032.

6.

BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.

Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Aydın O, Altiok E, Giray S, Azizlerli H.

Endocrine. 2012 Oct;42(2):404-10.

PMID:
22426956
7.

Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P.

J Clin Endocrinol Metab. 2010 Sep;95(9):4197-205. doi: 10.1210/jc.2010-0337.

PMID:
20631031
8.

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.

Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA.

J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. doi: 10.1210/jc.2013-1584.

PMID:
23969188
9.

TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M.

J Clin Endocrinol Metab. 2014 Jun;99(6):E1130-6. doi: 10.1210/jc.2013-4048.

10.

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.

Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.

Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008.

PMID:
24721322
11.
12.

BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.

Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP.

Laryngoscope. 2014 Sep;124(9):E389-93. doi: 10.1002/lary.24668.

PMID:
24604709
13.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Paulson L, Shindo M, Schuff K, Corless C.

Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):44-9. doi: 10.1001/archoto.2011.226.

PMID:
22249628
14.

The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.

Czarniecka A, Kowal M, Rusinek D, Krajewska J, Jarzab M, Stobiecka E, Chmielik E, Zembala-Nozynska E, Poltorak S, Sacher A, Maciejewski A, Zebracka-Gala J, Lange D, Oczko-Wojciechowska M, Handkiewicz-Junak D, Jarzab B.

PLoS One. 2015 Jul 15;10(7):e0132821. doi: 10.1371/journal.pone.0132821.

15.

[Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].

Shi C, Qin H, Ding C, Sun Y, Lyu Y, Shi T.

Zhonghua Zhong Liu Za Zhi. 2015 Feb;37(2):123-7. Chinese.

PMID:
25975689
16.

BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.

Ma YJ, Deng XL, Li HQ.

J Huazhong Univ Sci Technolog Med Sci. 2015 Aug;35(4):591-9. doi: 10.1007/s11596-015-1476-4.

PMID:
26223933
17.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169.

PMID:
24679337
18.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
19.

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V.

JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.

20.

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.

Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS.

PLoS One. 2014 Oct 22;9(10):e110868. doi: 10.1371/journal.pone.0110868.

Items per page

Supplemental Content

Support Center